Abstract: Disclosed herein are microfluidized lysate preparations of Leishmania parasites and methods of making thereof. Also disclosed are methods of using the microfluidized lysate preparations in skin test antigen assays as well as kits comprising the microfluidized lysate preparations. The microfluidized lysate preparations are made under current good manufacturing practice and may therefore be standardized and such preparations may be produced with consistently.

Abstract: This invention is directed to a composition comprising 4-chloro-3,6-dinitrobenzotrifluoride and related compounds and method for using it to treat infections caused by organisms that have microtubules.

Abstract: The instant invention provides compositions containing as active agents paromomycin in combination with gentamicin. When given in combination, the compositions appear much more effective than when given alone. Furthermore, the compositions of the invention were found to be effective against several species of Leishmania that were not effectively inhibited by the prior art compositions.

Abstract: This invention is directed to heterocyclic and aromatic thiosemicarbazones seful in the treatment of filariasis and in an animal, including humans.

Abstract: A method for treating malaria which comprises to an afflicted host patient a therapeutically effective amount of a compound have the structure of formula I: ##STR1## wherein X is O or NH; R.sub.1 is H or two R.sub.1 groups on the same amidine group together represents --(CH.sub.2).sub.m --, wherein m=2, 3 or 4; R.sub.2 is H, NH.sub.2, Cl, NO.sub.2 ; R.sub.3 is H, CH.sub.3 or CH.sub.2 CH.sub.3 and n=2-6 or a pharmaceutically acceptable salt thereof provided that when X is O, both R.sub.2 and both R.sub.3 can not be H.

Abstract: This invention relates to a method for treating leishmaniasis which comprises administering to an afflicted host patient, a therapeutically effective amount of a compound having the following structure; ##STR1## wherein X is O or NH; R.sub.1 is H or two R.sub.1 of the same amidine group together represent --(CH.sub.2).sub.m -- wherein m=2, 3 or 4; R.sub.2 is H, NH.sub.2, OCH.sub.3, Cl or NO.sub.2 ; R.sub.3 is H, CH.sub.3 or CH.sub.2 CH.sub.3 and n=2-6 or a pharmaceutical acceptable salt thereof provided that X is O both R.sub.2 and both R.sub.3 cannot be H.

Abstract: Two substantially purified larval T. solium antigens found circulating in the cerebrospinal fluid of patients infected with T. solium, having molecular weights of 190 KD and 230 KD, are disclosed. These antigens, alone or in combination, may be used to diagnose or to follow the course of neurocysticercosis, caused by T. solium infection.

Abstract: Immunological methods are disclosed for diagnosing active human neurocysticercosis, including a serum test and a cerebrospinal fluid test. The serum test involves detecting an antibody in serum which recognizes at least one of three particular antigens isolated from Taenia solium larvae. The cerebrospinal fluid test involves detecting an antigen or antigens of larval origin, preferably by an ELISA technique.

Abstract: Immunological methods are disclosed for diagnosing active human neurocysticercosis, including a serum test and a cerebrospinal fluid test. The serum test involves detecting an antibody in serum which recognizes at least one of three particular antigens isolated from Taenia solium larvae. The cerebrospinal fluid test involves detecting an antigen or antigens of larval origin, preferably by an ELISA technique.